◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Ionis Pharmaceuticals Inc (IONS) EBITDA 2006–TTM

Name: Ionis Pharmaceuticals Inc (IONS) ebitda history 2006-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-16

Ionis Pharmaceuticals Inc annual ebitda for fiscal 2025 was -$287 million, an increase of 18.9% from -$354 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

IONS Annual EBITDA

EBITDA (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
EBITDA	—	($287M)	($354M)	($236M)	($228M)	($5M)	($155M)	$382M	($19M)	$36M	($37M)	($41M)	($23M)	($42M)	($43M)	($56M)	($39M)	($16M)	$4M	($26M)	($59M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IONS Quarterly EBITDA

EBITDA (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
EBITDA	—	($69M)	$4.6B	($103M)	$150M	($120M)	($81M)	($117M)	($38M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

EBITDA at Comparable Companies

APGE EBITDA — Apogee Therapeutics, Inc. Common Stock
PTGX EBITDA — Protagonist Therapeutics Inc
KRYS EBITDA — Krystal Biotech Inc
KYMR EBITDA — Kymera Therapeutics Inc
SYRE EBITDA — Spyre Therapeutics Inc.
CRNX EBITDA — Crinetics Pharmaceuticals Inc

More IONS metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding

All IONS financial statements → Interactive IONS charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.